Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168779 · ClinicalTrials.gov registry record · Phase 4
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,185
- Enrollment target
NCT00168779: Completed Phase 4 study, sponsored by Boehringer Ingelheim.
NCT00168779 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,185 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (129% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00168779, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,185 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
Interventions
- DRUG placebo
- DRUG telmisartan 80 mg / hydrochlorothiazide 25 mg
- DRUG valsartan 160 mg / hydrochlorothiazide 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,185 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 4 |
What the finished NCT00168779 record still lists
NCT00168779 is an interventional study that assigns participants to a tested intervention. Its 1,185 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (129% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00168779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00168779 about?
NCT00168779 is a clinical study titled "Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension". The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and placebo in the treatment of Stage 1 and Stage 2 hypertension.
What is the current status of trial NCT00168779?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,185 participants. The study started on 2005-09. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00168779?
The interventions under investigation include: placebo (DRUG), telmisartan 80 mg / hydrochlorothiazide 25 mg (DRUG), valsartan 160 mg / hydrochlorothiazide 25 mg (DRUG).
Who is sponsoring clinical trial NCT00168779?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00168779's enrollment target sits among peer trials
1,185 63rd of 2000 higher than 1,938 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia